ArticleFrontiers in cardiovascular medicine2026
Effect of stress-induced hyperglycaemia on clinical outcome in paitients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stress hyperglycemia (SHG) is a transient glycemic disturbance induced by acute stress, and its independent prognostic value in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) remains to be fully clarified. This study aimed to investigate the impact of SHG on short- and long-term outcomes in this population and evaluate its role in risk stratification. Methods: A retrospective analysis was conducted on 818 first-time STEMI patients who underwent emergency PCI between July 2020 and February 2024. Patients were classified into three groups based on diabetes history, fasting blood glucose (FBG) levels, and glycated hemoglobin (HbA1c) levels: 1) SHG group ( Results: The SHG group had significantly higher in-hospital all-cause mortality (IHACM; 13.4% vs. 2.19% in the non-SHG group, Conclusions: SHG is a strong independent risk factor for IHACM in STEMI patients, with potential mediation by acute metabolic disorders and endothelial injury. Notably, acute hemodynamic instability cannot be excluded as a contributing factor to the observed association, and further studies are needed to clarify the precise mediating pathways. Long-term prognosis is mainly influenced by baseline cardiac function and coronary artery disease severity. Incorporating SHG (defined as FBG ≥7.0 mmol/L in non-diabetic patients with HbA1c < 6.5%) into early risk stratification and developing individualized management strategies for acute-phase glucose fluctuations are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.